Trial Profile

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 31 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rezpegaldesleukin (Primary)
Indications Atopic dermatitis
Focus Adverse reactions; Proof of concept
Sponsors Eli Lilly and Company; Nektar Therapeutics

Most Recent Events

28 Oct 2024 According to a Nektar Therapeutics media release, data from this trial presented in theNature Communications.
28 Oct 2024 Results presented in the Nektar Media Release.
25 Sep 2024 According to a Nektar Therapeutics media release, New proteomic analysis presentation from this trial for rezpegaldesleukin (REZPEG) presented at the 2024 European Academy of Dermatology and Venereology (EADV) Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com